Clinical and regulatory failure
Pipeline assets are still in development and may never achieve pivotal success or marketing approval.
- Scope
- Silevertinib and other oncology candidates
- Materiality
- high
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage precision oncology company focused on discovering and developing small-molecule therapies for genetically defined cancers. Its pipeline is built around targeting oncogenic mutations in solid tumors, including RAF/RAS-mutant disease and EGFR-mutant non-small cell lung cancer (NSCLC). The company does not have any approved products and has not generated product sales; historically, revenue has come from licensing intellectual property. In March 2025, Black Diamond entered into a global licensing agreement with Servier for BDTX-4933, shifting development and commercialization responsibility for that asset to a partner while retaining potential milestone and royalty economics. The company remains dependent on external financing, collaborations, and successful clinical execution to advance its remaining programs.
18,4 %
32,0 %
8.42
8.42
| % | |
|---|---|
| Clinical-stage oncology assets | 0% Small-molecule drug candidates in preclinical and clinical development for genetically defined solid tumors. |
| Licensing and collaboration revenue | 100% Upfront payments, milestones, and royalties from out-licensing product candidates and related intellectual property. |
Black Diamond's direct counterparties are pharmaceutical partners rather than end patients, because the company...
- Pharmaceutical licensing partnersprimary
Large biopharma companies that pay upfront fees, milestones, and royalties to obtain development and commercialization rights to Black Diamond's assets.
- Strategic development collaboratorsprimary
Partners that may co-fund or lead clinical development of pipeline programs such as silevertinib in exchange for rights or economics.
- Future oncology prescribers and treatment centersemerging
Hospitals, cancer centers, and oncologists that would use approved therapies if the company's candidates reach commercialization.
- Patients with mutation-defined solid tumorsemerging
Patients with RAF/RAS-mutant cancers, EGFR-mutant NSCLC, or other genetically defined tumors targeted by the pipeline.
Black Diamond is headquartered in the United States and its current operating footprint is centered on U.S...
- •Headquartered in the United States, where corporate and R&D activity is concentrated
- •Exposure to U.S. FDA regulation and U.S. healthcare reimbursement policy
- •Global rights for BDTX-4933 under the Servier licensing agreement
- •Potential future commercialization would likely span multiple regions if assets are approved
- •No country-level revenue disclosure was provided in the excerpts
Black Diamond's near-term strategy is to extend cash runway while advancing its clinical oncology pipeline through...
01
Partner and out-license clinical assetsshort-term
Partnerships reduce capital needs and transfer development/commercialization burden to larger pharma companies.
02
Extend cash runway through disciplined spendingshort-term
The company has no product sales and must fund operations until it can secure approvals or additional capital.
03
Advance mutation-targeted oncology programsmedium-term
Clinical progress is required to create partnering leverage, milestone potential, and eventual product value.
Black Diamond faces the classic risks of a clinical-stage biotechnology company: it has no approved products, no...
Dependence on Servier to develop and commercialize BDTX-4933
Black Diamond has granted Servier a worldwide license, so future value from that asset depends on Servier's execution, funding, and regulatory success.
- Scope
- BDTX-4933
- Materiality
- high
Need for additional financing
The company expects current cash to fund operations only into the fourth quarter of 2027 and may need to raise capital thereafter.
- Scope
- Corporate liquidity and pipeline funding
- Materiality
- high
U.S. pricing and reimbursement pressure
State and federal healthcare reforms, pricing controls, and payer bidding can reduce demand and pricing for approved products.
- Scope
- Future commercial products
- Materiality
- medium
Regulatory agency disruption
Inadequate funding or operational constraints at the FDA and other agencies could slow reviews and commercialization pathways.
- Scope
- Clinical and regulatory timelines
- Materiality
- medium
ASC 606 license revenue
Upfront payment from Servier and future milestone/royalty accounting
Clinical trial expense timing
Quarterly operating loss comparability
Operating leases
Lease liabilities and liquidity analysis
Revolution Medicines, Inc.
RVMD · Biological Products, (No Diagnostic Substances)
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
IDEAYA Biosciences, Inc.
IDYA · Pharmaceutical Preparations
IDEAYA Biosciences is a clinical-stage precision oncology company focused on discovering and developing targeted cancer therapies matched to specific molecular alterations.
Beam Therapeutics Inc.
BEAM · Biological Products, (No Diagnostic Substances)
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
BridgeBio Oncology Therapeutics, Inc.
BBOT · Pharmaceutical Preparations
: 11/08/2026